Generic placeholder image

Current Pharmaceutical Design

Author(s): Jianping Yong and Canzhong Lu*

DOI: 10.2174/0113816128282194240329045625

DownloadDownload PDF Flyer Cite As
Synthesis of Rupestonic Acid L-Ephedrine Derivatives with Preliminary In vitro Anti-influenza Viral Activity

Page: [1398 - 1403] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Background: Influenza virus is a kind of RNA virus. Nowadays, the high incidence of influenza and the morbidity and mortality of epidemic influenza are substantial. It has been reported that one hundred million people in the world are infected with influenza viruses, and two hundred and fifty thousand to five hundred thousand people die from the flu per year. In 2021, the number of infected persons in China was reported to be 654,700, and 0.07% of the infected persons died. The flu has caused a serious threat to human survival. Although several drugs, such as Zanamivir, Oseltamivir, Peramivir, and Laninamivir, have been used in clinics for the treatment of the influenza virus, there are some shortcomings of these drugs. The strain of influenza H5N1 (avian influenza) has been found to resist the effective drug Oseltamivir. Thus, there is an urgent demand to discover new influenza virus inhibitors to overcome the emergence of influenza antigens.

Aims : This study aimed to develop new influenza virus inhibitors based on the rupestonic acid parent core.

Objective: The rupestonic acid L-ephedrine ester (A) and rupestonic acid L-ephedrine complex (B) were synthesized in this work for the development of influenza virus inhibitors.

Methods: The target compounds were synthesized using rupestonic acid and L-ephedrine as starting materials. Their structures were characterized by 1H NMR and 13C NMR, and the purity was determined by HPLC. Then, their preliminary in vitro influenza activity was evaluated using Oseltamivir as a reference drug.

Results: The results showed that the synthesized rupestonic acid L-ephedrine derivatives A and B were more potent influenza virus inhibitors against the strains of A/PR/8/34 (H1N1) and A/FM/1/47 (H1N1) with the IC50 values of 51.0, 51.0 μM and 441.0, 441.0 μM, respectively, than that of rupestonic acid. By comparing the IC50 of compounds A and B, compound A can be regarded as a very promising lead compound for the development of influenza virus inhibitors.

Conclusion: The rupestonic acid L-ephedrine ester (A) and rupestonic acid L-ephedrine complex (B) were synthesized and characterized using 1H NMR and 13C NMR. Moreover, their purity was determined by HPLC. Both compounds A and B exhibited more potent activities against the strains of A/PR/8/34 (H1N1) and A/FM/1/47 (H1N1) than rupestonic acid. Compound A can be regarded as a very promising lead compound for the development of influenza virus inhibitors. Based on these results, more rupestonic acid derivatives will be designed and synthesized in the future for the development of influenza virus inhibitors.

[1]
Taisuke H, Yoshihiro K. Influenza: Lessons from past pandemics, warning from current incidents. Natl Rev 2005; 3: 591-600.
[2]
Ge H, Wang YF, Xu J, et al. Anti-influenza agents from traditional Chinese medicine. Nat Prod Rep 2010; 27(12): 1758-80.
[http://dx.doi.org/10.1039/c0np00005a] [PMID: 20941447]
[3]
Yoon SW, Webby RJ, Webster RG. Influenza pathogenesis and control-volume I. Curr Top Microbiol 2014; 385: 359-75.
[4]
(a) Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008; 453(7199): 1258-61.
[http://dx.doi.org/10.1038/nature06956] [PMID: 18480754];
(b) Le QM, Kiso M, Someya K, et al. Isolation of drug-resistant H5N1 virus. Nature 2005; 437(7062): 1108.
[http://dx.doi.org/10.1038/4371108a] [PMID: 16228009];
(c) Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA 2000; 283(8): 1016-24.
[http://dx.doi.org/10.1001/jama.283.8.1016] [PMID: 10697061]
[5]
(a) Aisa HJ, Yong JP, Lv QY, Wu T. (5R,8R)-2-(3,8-Dimethyl-2-oxo-1,2,4,5,6,7,8,8a-octahydroazulen-5-yl)acrylic acid (rupestonic acid). Acta Crystallogr 2008; E64: o479. (b) Yong JP, Aisa HJ. The preparation, purity determination by HPLC and structural elucidation of rupestonic acid. Comput Appl Chem 2011; 28(5): 535-9.
[6]
Yong JP. Synthesis of rupestonic acid derivatives and in vitro inhibition against influenza and herpes simplex viral activities. PhD Thesis. Beijing: University of Chinese Academy of Sciences 2008.
[7]
Zhao JY. Study on synthesis and anti-influenza activity of candidate compounds based on rupestonic acid skeleton. PhD Thesis. Beijing: University of Chinese Academy of Sciences 2011.
[8]
He YW. Study on the synthesis and bioactivity of rupestonic acid derivatives as potential influenza virus agents based on the click chemistry and fructodiketoyl-guanidines. PhD Thesis. Beijing: University of Chinese Academy of Sciences 2013.
[9]
Obul M. Study on the structural modification of 2-methylene and exocyclic alkene of rupestonic acid and anti influenza virus activity of its derivatives. PhD Thesis. Beijing: University of Chinese Academy of Sciences 2021.
[10]
Chen L. Synthesis and anti-influenza activity of rupestonic acid derivatives with acyl and triazole. PhD Thesis. Beijing: University of Chinese Academy of Sciences 2022.
[11]
Yumaier A, Cui ZC, Abudurixiti A, Yusuf A. Development and structural modifications of rupestonic acid derivatives as novel anti-influenza agents: A mini review of the last 10 years. Chemistry-Select 2022; 7(30): e202201906.
[http://dx.doi.org/10.1002/slct.202201906]
[12]
Zhao J, Niu C, Li G, Aisa HA. Synthesis of rupestonic acid derivatives with antiviral activity. Chem Nat Compd 2017; 53(2): 276-83.
[http://dx.doi.org/10.1007/s10600-017-1970-y]
[13]
Zhao JY, Dong CZ, Haji AA. Synthesis and in vitro anti-influenza evaluation of rupestonic acid analogues: effect of configuration and substitution at C (3). Med Chem 2016; 6(5): 232-6.
[14]
Yong JP, Aisa HA. Chemical modification of rupestonic acid and preliminarily in vitro antiviral activity against influenza A3 and B viruses. Bull Korean Chem Soc 2011; 32(4): 1293-7.
[http://dx.doi.org/10.5012/bkcs.2011.32.4.1293]
[15]
Yong J, Lu C, Aisa HA. Advances in studies on the rupestonic acid derivatives as anti-influenza agents. Mini Rev Med Chem 2013; 13(2): 310-5.
[PMID: 22625417]
[16]
Yong JP, Zhao JY, Aisa HA. Synthesis of 3-deoxy rupestonic acid and its activity against Flu virus in vitro. Lishizhen Med Mat Med Res 2011; 22(1): 19-21.
[17]
Yong JP, Lv QY, Aisa HA. Synthesis of (5R,8R)-2-(3,8-dimethyl-2-oxo-1,2,4,5,6,7,8,8α-octahydroazulen-5-yl) acrylic acid(rupestonic acid) amide derivatives and in vitro inhibitive activities against influenza A3, B and herpes simplex type 1 and 2 virus. Bull Korean Chem Soc 2009; 30(2): 435-40.
[http://dx.doi.org/10.5012/bkcs.2009.30.2.435]
[18]
Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45(3): 743-8.
[http://dx.doi.org/10.1128/AAC.45.3.743-748.2001] [PMID: 11181354]